Assena Stoimenova, member of the management board of the European Medicines Agency (EMA) and executive director of the Bulgarian Drug Agency (BDA), explains the Agency’s evolution under her tenure as well as her commitment to ensuring that the BDA remains predictable, transparent and fair, being fully focused on safeguarding patients and society’s interests.
Ms. Stoimenova, you were appointed as Executive Director of the Bulgarian Drug Agency (BDA) in July 2014. How would you assess the evolution of the institution under your tenure?
"Looking to the BDA’s next steps, we are aiming to further expand our capabilities in conducting GMP inspections in Asia by 2017/2018."
